Inovio Pharmaceuticals
Clinical trials sponsored by Inovio Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing DNA-based immunotherapies and vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy targets aggressive brain cancer Results expected Dec 2026 (estimated)
-
New DNA vaccine shows promise against deadly MERS virus
Vaccine CompletedThis Phase 2 trial tested a new DNA vaccine called INO-4700 in 192 healthy adults to see if it is safe and can trigger an immune response against MERS, a serious coronavirus. The vaccine is given as a shot under the skin followed by a quick electric pulse to help cells take up th…
Phase 2 • Sponsor: Inovio Pharmaceuticals • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
-
Can DNA vaccines plus immunotherapy shrink hard-to-treat bladder cancer?
Disease control CompletedThis trial tests whether combining two DNA-based immunotherapies with the drug atezolizumab can help people with advanced urothelial carcinoma, a type of cancer of the bladder and urinary tract. The DNA therapies are injected into muscle and followed by a brief electric pulse to …
Phase 1/2 • Sponsor: Inovio Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
DNA vaccine shows promise in cutting surgeries for rare throat tumor disease
Disease control CompletedThis study tested a new DNA vaccine called INO-3107 in 32 adults and children with recurrent respiratory papillomatosis (RRP), a rare condition where non-cancerous tumors grow in the airway due to HPV-6 or HPV-11. The vaccine was given with a device that uses electrical pulses to…
Phase 1/2 • Sponsor: Inovio Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC